UK Shareholder Meetings Calendar - Next 7 Days
Tuesday 15 MayAmerisur ResourcesMacfarlane GroupSpirax-Sarco EngineeringAnglo Pacific
Read moreMon, 22nd Aug 2016 11:57
Tuesday 15 MayAmerisur ResourcesMacfarlane GroupSpirax-Sarco EngineeringAnglo Pacific
Read moreLONDON (Alliance News) - Biotherapeutics developer 4D Pharma PLC said on Tuesday that the US Food & Drug Administration has cleared the Investigational New Drug Application for irritable bowel
Read moreLONDON (Alliance News) - Drug development firm 4D Pharma PLC said Monday its loss widened in 2017 on higher research and development costs as it continued to progress its pipeline and clinical in
Read moreLONDON (Alliance News) - 4D Pharma PLC on Wednesday said it is close to starting clinical studies on its potential MRx0518 cancer treatment.MRx0518 is a single strain a
Read more(ShareCast News) - 4D Pharma announced a positive response from its Blautix treatment for irritable bowel syndrome (IBS) in a phase 1 clinical trial. The trial was a first in man study and, as previously reported by the company, Blautix was found to be both safe and well tolerated and achieved the p
Read more(ShareCast News) - Early clinical trials of 4D Pharma's treatment for irritable bowel syndrome (IBS) have successfully shown Blautix to be safe and well tolerated. Blautix, which contains live bacteria, like all 4D's products, was delivered orally to 56 healthy volunteers and IBS patients. Data fro
Read more(ShareCast News) - 4D Pharma announced a major acquisition on Friday, gobbling up the production assets of Spanish-based contract research organisation Biomar. The AIM-traded pharmaceutical company, which focuses on the development of live biotherapeutics, said Biomar had been working as an outsourc
Read more